Asia Deal Watch: Eisai Advances Portfolio Focus With Divestiture Of Two Products To DKSH
Executive Summary
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
You may also be interested in...
Lupin Expands US Inhalation Business With Two Sunovion Brands
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
Myovant Accepts Higher Sumitovant Offer In Deal That Values It At $2.9bn
Sumitovant, a Sumitomo subsidiary, will pay $27 per share for the 48% of Myovant shares it does not already own, for a deal value of $1.7bn, up from a $22.75-per-share bid in early October.
Bluebird Spinoff 2seventy Bio Gets Its Own Wings
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.